Effector T cell anergy induction

Effector T cell anergy induction refers to the process by which effector T cells become functionally unresponsive following antigen encounter, typically due to incomplete activation signals. This state is characterized by hyporesponsiveness—T cells remain alive but fail to proliferate or produce cytokines upon restimulation with their specific antigen. Molecularly, this is often triggered when the T cell receptor (TCR) is engaged without adequate co-stimulatory signals, leading to disproportionate activation of calcium/NFAT signaling relative to other pathways such as Ras/MAPK. The result is upregulation of negative regulatory genes including Egr2 and Egr3 transcription factors and proteins like DGK‐α and certain E3 ubiquitin ligases that suppress further signaling through the TCR pathway[1][3][4]. Anergy serves as a key mechanism for peripheral immune tolerance, preventing self-reactive lymphocytes from causing autoimmunity while also representing a barrier in cancer immunotherapy where reversing anergy could restore anti-tumor responses[1][5]. Markers associated with the anergic state include increased expression of CD73, FR4, PD‐1, and especially Egr2; these can be used experimentally as biomarkers for identifying or monitoring effector T cell anergy[4]. "Effector T cell anergy induction" does not refer to a discrete molecular target such as a receptor or enzyme but rather describes a complex cellular process involving multiple molecular players. Therefore it should not be considered a canonical therapeutic target itself; instead, individual molecules involved in this pathway may serve as drug targets. Because "Effector T cell anergy induction" names a biological process rather than any single molecule or receptor—and thus does not fit standard conventions for molecular targets—the entry is marked as incorrect for use in structured drug-target databases.

Other names

T cell anergy inductionClonal anergy inductionAnergy induction in effector T cells